Nexvet Biopharma (NASDAQ: NVET) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Nexvet Biopharma to related businesses based on the strength of its institutional ownership, valuation, earnings, risk, profitability, dividends and analyst recommendations.

Valuation & Earnings

This table compares Nexvet Biopharma and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Nexvet Biopharma N/A N/A -3.84
Nexvet Biopharma Competitors $284.28 million $34.29 million 135.04

Nexvet Biopharma’s competitors have higher revenue and earnings than Nexvet Biopharma. Nexvet Biopharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Nexvet Biopharma and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nexvet Biopharma 0 1 0 0 2.00
Nexvet Biopharma Competitors 846 3197 11593 230 2.71

Nexvet Biopharma presently has a consensus price target of $6.72, suggesting a potential upside of 0.00%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.97%. Given Nexvet Biopharma’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Nexvet Biopharma has less favorable growth aspects than its competitors.

Profitability

This table compares Nexvet Biopharma and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nexvet Biopharma N/A -102.72% -89.82%
Nexvet Biopharma Competitors -5,306.52% -432.90% -39.18%

Institutional & Insider Ownership

48.4% of Nexvet Biopharma shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 37.0% of Nexvet Biopharma shares are owned by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Nexvet Biopharma competitors beat Nexvet Biopharma on 7 of the 10 factors compared.

Nexvet Biopharma Company Profile

Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company’s platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal’s immune system, a property referred to as 100% species-specificity. PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals. Biologics generally include mAbs, which are targeted antibodies derived from identical (clonal) cells. The Company’s advanced product candidates are in pivotal-phase development: ranevetmab (or NV-01) and frunevetmab (or NV-02).

Receive News & Ratings for Nexvet Biopharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexvet Biopharma plc and related companies with MarketBeat.com's FREE daily email newsletter.